The UMC Utrecht is nationally and internationally renowned and is one of the largest academic centers in the Netherlands.
In co-operation with regional, national and international partners, the UMC works on solutions for major medical problems.
Patient care and biomedical research are in this institution closely linked. The innovative strength is focus on a select number of key strategy programs that integrate leading research and healthcare and drive the ‘clinical need loop’ of scientific research, education and innovative care.
These key strategy programs are organised into division- and discipline-wide programmes. This stimulates co-operation and helps to focus maximum attention and strategic resources on creating innovative treatments.
Lead Scientist: Dr. Ineke Slaper-Cortenbach
Institution: University Medical Centre Utrecht (UMCU)
Position: Medical Biologist
Telephone: (+) 31 88 7556574
Dr. Ineke Slaper-Cortenbach (female) is an internationally established leading authority in regulatory affairs of cellular products and head of the Cell Therapy Facility (CTF) in the UMC Utrecht with more than 25 years experience as a laboratory director of cell therapy. Her expertise is also reflected by taking lead in multiple national and international organizations: i.e. (past)presidency for JACIE, several positions within ISCT (i.e for 7 years she was the chair of the European LRA Committee), Expert on the Working Party on Cell Therapeutic Products of the European Pharmacopeia Committee and member of the Dutch Expert Group on ATMPs. She will be a member of the Cell Processing Committee of the EBMT.
The CTF was the first academic hospital to achieve GMP-accreditation in the Netherlands and has a license for the production of all ATMP classes not only for national but also for international partners. Her main interest in research is the development of GMP-approved manufacturing procedures for ATMPs. Examples are Mesenchymal Stromal Cells, which are currently manufactured animal-protein free using platelet lysate for multiple trials and Minor histocompatibility antigen-based Dendritic Cell vaccination.
Tasks: Dr. Slaper-Cortenbach leads WP 5 assisted by a pharmacist employed by this grant. She also participates in WP2, 3 and 4.
1. Ivan Martin, Helen Baldomero, Chiara Bocelli-Tyndall, Ineke Slaper-Cortenbach, Jakob Passweg, Alan Tyndall. The survey on cellular and engineered tissue therapies in Europe in 2009: focus on autoimmune disease. Tissue Engineering Part A Sep;17(17-18):2221-2230, 2011
2. Alois Gratwohl, Ronald Brand, Dietger Niederwieser, Helen Baldomero, Christian Chabannon, Jan Cor- nelissen, Theo de Witte, Per Ljungman, Fiona McDonald, Eoin McGrath, Jakob. Passweg, Christina Peters, Vanderson Rocha, Ineke Slaper-Cortenbach, Anna Sureda, Andre Tichelli, Jane Apperley. Introduction of a quality management system and outcome after hematopoietic stem cell transplantation. JCO May 20: 29 (15): 1980-1988, 2011
3. Ineke Slaper-Cortenbach. ISBT 128 coding and labeling for cellular therapy products. Cell. Tissue Bank 11 (4): 375-378, 2010
4. Jaap Oostendorp, Anna de Goede, Ineke Slaper-Cortenbach. Advanced Therapy Medicinal Products – entering the hospital pharmacy arena. EJHP 16:53-55, 2010
5. Slaper-Cortenbach I, Scott M, Hermann D, Introna M, Theunissen K, Theocharous P, and Chabannon C. Chapter 2 – Regulatory Section 2.2 – The Regulatory Situation for Academic Cell Therapy Facilities in Europe. Cell Therapy: cGMP Facilities and Manufacturing. Edited by Adrian Gee, PhD 2009. ISBN: 978-0- 387-89583-3